Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Liikkuvuuden parantaminen perifeerisen valtimotaudin revaskularisoinnin jälkeen (IMPACT PAD)

keskiviikko 30. syyskuuta 2026 päivittänyt: Mary McDermott, Northwestern University

Liikkuvuuden parantaminen perifeeristen valtimotautien revaskularisaation jälkeen: IMPACT PAD -tutkimus

Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.

Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity.

In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

More than 300,000 surgical or endovascular lower extremity revascularization procedures are performed annually for Medicare beneficiaries who have lower extremity peripheral artery disease (PAD) without limb threatening ischemia, and rates of these procedures are increasing. In these patients, revascularization typically improves, but does not eliminate, PAD related walking impairment. Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD.

Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. A large body of evidence, assembled over more than 25 years, supports our hypothesis that inorganic nitrate (such as that in nitrate-rich beetroot juice) will improve walking performance and other lower extremity outcomes after lower extremity revascularization.

Effective, accessible, and safe therapies are needed to enhance the benefits and improve durability of lower extremity revascularization. Therefore, in a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2). In Secondary Aims, the trial will establish whether home-based exercise, compared to control, and whether nitrate-rich beetroot juice, compared to placebo, improve the Walking Impairment Questionnaire and the PROMIS Mobility Questionnaire and prevent hemodynamic failure of the revascularized vessel. In exploratory aims, the trial will test the effects of the interventions on plasma nitric oxide bioavailability. If our hypotheses are correct, results of this trial will have a major impact on improving mobility in the large and growing number of people undergoing revascularization for disabling PAD.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

386

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Arizona
      • Tucson, Arizona, Yhdysvallat, 85724
        • Rekrytointi
        • University of Arizona
        • Ottaa yhteyttä:
          • Wei Zhou, MD
    • California
      • Downey, California, Yhdysvallat, 90242
        • Rekrytointi
        • Rancho Research Institute
        • Ottaa yhteyttä:
          • Tze-Woei Tan, MD
    • Florida
      • Tampa, Florida, Yhdysvallat, 33606
        • Rekrytointi
        • University of South Florida
        • Ottaa yhteyttä:
          • Ulka Sachdev, MD
    • Georgia
      • Atlanta, Georgia, Yhdysvallat, 30307
        • Rekrytointi
        • Emory University School of Medicine
        • Ottaa yhteyttä:
          • Olamide Alabi, MD
    • Illinois
      • Chicago, Illinois, Yhdysvallat, 60637
        • Rekrytointi
        • University of Chicago
        • Ottaa yhteyttä:
          • Tamar Polonsky, MD
          • Puhelinnumero: 773-702-6153
      • Chicago, Illinois, Yhdysvallat, 60611
        • Rekrytointi
        • Northwestern University Feinberg School of Medicine
        • Päätutkija:
          • Mary M McDermott, MD
        • Ottaa yhteyttä:
    • Michigan
      • Detroit, Michigan, Yhdysvallat, 48202
        • Rekrytointi
        • Henry Ford Health
        • Ottaa yhteyttä:
          • Jonathan Ehrman, PhD
    • New Hampshire
      • Lebanon, New Hampshire, Yhdysvallat, 03766
        • Rekrytointi
        • Dartmouth Hitchcock Medical Center
        • Ottaa yhteyttä:
          • Philip P Goodney, MD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

Successful lower extremity revascularization for disabling PAD performed at least 30 days before baseline testing and between 30 and 100 days before randomization.

Exclusion Criteria:

  1. History of leg amputation, not including toe and partial foot amputation
  2. Active gangrene
  3. Active limb threatening ischemia
  4. Already exercising at a level consistent with exercise intervention, using investigator discretion.
  5. Unstable angina
  6. Unwilling to drink study beverages
  7. Unwilling to adhere to the interventions and complete follow-up testing
  8. Currently taking sildenafil, tadalafil, or related drugs.
  9. Unwilling to accept randomization into either group (home-based exercise or attention control)
  10. Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and/or unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.
  11. History of kidney stones that requires minimized intake of oxalate. Potential participants who need to minimize oxalate intake will be excluded from the trial.
  12. Baseline blood pressure <100/45.
  13. Wheelchair confinement or requiring a walker to ambulate
  14. Walking is limited by a condition other than PAD
  15. Current foot ulcer
  16. Planned major surgery, coronary revascularization, or lower extremity revascularization during the next 12 months
  17. Major medical illness including lung disease requiring oxygen, Parkinson's disease, or a life-threatening illness with life expectancy less than six months.
  18. Allergy to beetroot juice
  19. Currently consuming one cup or more of beets daily. Participants will be asked to decrease beet consumption to less than one cup of beets per day for 14 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.
  20. Participation in or completion of a clinical trial in the previous three months, using investigator discretion for trials that may not impact study participation or outcome measures of the IMPACT PAD Trial.
  21. Visual impairment that limits walking ability.
  22. Unable to communicate in English, unless the participant communicates in Spanish and is enrolled at a site that can deliver the intervention in Spanish. All sites with a Spanish speaking coordinator and interventionist will be able to enroll Spanish-speaking participants. While investigators aim to be as inclusive as possible, resources are not available to allow inclusion of people speaking languages that are not Spanish or English.
  23. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
  24. Planning to begin a supervised treadmill exercise program in the next 12 months.
  25. Heart attack or stroke in previous three months prior to baseline testing.
  26. An eGFR value <30 or potassium >5.0.
  27. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Tehtävätehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Home based exercise + nitrate rich beetroot juice

This group will be participating in home based exercise and drinking nitrate rich beetroot juice for six months.

This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention

Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Placebo Comparator: Home-based exercise + placebo

This group will be participating in home based exercise and drinking placebo beetroot juice with nitrate removed for six months.

This is a six month intervention where participants will walk at home for exercise with guidance from a study coach. They will attend two to four weekly meetings with the coach at the clinical site in the first 4 weeks following randomization, followed by once weekly telephone coaching calls for the remainder of the six-month intervention

Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Kokeellinen: Attention control + nitrate-rich beetroot juice

This group will be participating in attention control and drinking nitrate rich beetroot juice for six months.

Participants will drink one shot of nitrate rich beet-root juice twice daily for six months.

Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Placebo Comparator: Attention control + placebo

This group will be participating in attention control and drinking placebo beetroot juice with nitrate removed for six months.

Participants will drink one shot of placebo beetroot without nitrate juice twice daily for six months.

Participants will be asked to participate in weekly meetings with the coach in the attention control group for weeks 1-26. A staff member will present a topic from the National Institute on Aging "age pages" relevant to health, such as cancer screening or blood pressure treatment. Calls will last approximately 5-15 minutes and will focus on educational topics such as diabetes, healthy eating, and Medicare Part D.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Six-Minute Walk Distance 6-month change
Aikaikkuna: Baseline to 6-month follow-up

Distance walked in six minutes

Baseline to 6-month follow-up

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Walking Impairment Questionnaire (WIQ) Distance Score 6-month change
Aikaikkuna: Baseline to 6-month follow-up.

Patient reported ability to walk long distances. Score Range 0-100, 100 is best.

Baseline to 6-month follow-up.
Walking Impairment Questionnaire (WIQ) Distance Score 12-month change
Aikaikkuna: Baseline to 12-month follow-up

Patient reported ability to walk long distances. Score Range 0-100, 100 is best.

Baseline to 12-month follow-up
PROMIS Mobility Questionnaire Score 6-month change
Aikaikkuna: Baseline to 6-month follow-up

Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome.

Baseline to 6-month follow-up
PROMIS Mobility Questionnaire Score 12-month change
Aikaikkuna: Baseline to 12-month follow-up.

Patient report of mobility in daily living. Score range is from zero to infinity and a higher score means a better outcome.

Baseline to 12-month follow-up.
Prevention of Hemodynamic Failure of The Revascularized Vessel
Aikaikkuna: Baseline to 12 month follow-up

Hemodynamic failure consists of loss of patency of the revascularized vessel. The outcome will be adjudicated as a categorical outcome. Medical records between randomization and final follow-up will be obtained and reviewed by the IMPACT PAD adjudication committee, consisting of field center investigators and an interventional cardiologist. Participants who meet pre-defined criteria for hemodynamic failure of the revascularized vessel.

Baseline to 12 month follow-up
Change in 6-minute walk distance
Aikaikkuna: 12 month follow-up

Change in 6-minute walk distance between baseline and 12-month follow-up

12 month follow-up

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Six-Minute Walk Distance
Aikaikkuna: Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink

Change in six-minute walk distance 24 hours after the final study beverage

Baseline to six-month follow-up at the time point that is twenty-four hours after the final study drink
Plasma Nitrite Levels
Aikaikkuna: Baseline to 6-month follow-up

Change in plasma nitrite levels in the blood at 6-month follow-up

Baseline to 6-month follow-up
BH4/BH2 6-month change
Aikaikkuna: Baseline to 6-month follow-up

Change in BH4/BH2 ratio

Baseline to 6-month follow-up
Progression of PAD
Aikaikkuna: Baseline to 12-month follow-up

Determine whether home-based walking exercise, compared to attention control prevents progression of PAD, defined by any new lower extremity revascularization, acute limb ischemia, or amputation of either lower extremity between baseline and 12-month follow-up.

Baseline to 12-month follow-up

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Maanantai 4. elokuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 1. helmikuuta 2032

Opintojen valmistuminen (Arvioitu)

Sunnuntai 1. elokuuta 2032

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Perjantai 8. marraskuuta 2024

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 12. marraskuuta 2024

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 13. marraskuuta 2024

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 5. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 30. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • STU00222333

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-jaon aikakehys

Data will be available at the time the primary outcome manuscript is submitted for publication and will be available for up to 10 years.

IPD-jaon käyttöoikeuskriteerit

Per BioLINCC

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • ICF

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .